Profile: Aquestive Therapeutics Inc (AQST.OQ)
Aquestive Therapeutics, Inc., incorporated on March 5, 2007, is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). The Company’s products are developed using a PharmFilm technology that provides an oral film. The films are categorized based on types of deliveries that include buccal delivery, sublingual delivery and lingual delivery. It conducts its research and develops treatments for CNS related disease through its CNS programs. Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis.
The Company's complex molecule programs consist of AQST-108, and AQST-305. AQST-108 is a sublingual film formulation of epinephrine for the treatment of anaphylaxis and AQST-305 is a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. AQST-108 and AQST-305 is in the Phase I of development. The Company also has a pipeline of products developed under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
The Company competes with Valeant Pharmaceuticals International, Inc., Lundbeck A/S, Eisai Co., Mitsubishi Tanabe Pharma Corporation, Mylan Inc., Novartis AG, and Pfizer Inc.
Aquestive Therapeutics Inc
30 Technology Dr
WARREN NJ 07059-5166